Fig. 4
GPS2 represses PPARα-regulated promoters and enhancers. a GPS2, H3K4me3, H3K27ac, and H3K4me1 ChIP-seq peaks are aligned to the GPS2 peak center in a window of ±3 kb. b, c ChIP-seq tracks of GPS2, H3K27ac, and H3K4me3 peaks at (b) Pdk4 and (c) Cyp4a14 loci, percentage of increase (LKO versus WT) represents logFC of each peak and is calculated from biological duplicates. d, e ChIP-seq tracks of GPS2, PPARα (vehicle and GW7647 treated, GSE61817) peaks at (d) Pdk4 and (e) Cyp4a14 loci. f Venn diagram representing the overlapped GPS2 and PPARα peaks detected at least twice in mouse liver. g Further ChIP qPCR validation of H3K27ac at Pdk4 promoter (upper left), Pdk4 enhancer (upper right), Cyp4a14 promoter (lower left) and control (lower right) locus in WT, LKO, PKO, and PGKO livers, n = 5 in WT and LKO groups, n = 4 in PKO group and n = 3 in PGKO group, one-way ANOVA followed by Tukey’s test. All data are represented as mean ± s.e.m.*P < 0.05, **P < 0.01, ***P < 0.001
